Results 231 to 240 of about 77,958 (315)

Prescribing variation across Europe: Insights into prescribing practices and educational needs

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing medication is a complex process, influenced by many factors that can be weighed differently. Four prescriber profiles have been identified: pragmatic‐contextual, guideline‐oriented, experience‐driven and vulnerability‐focused. However, the extent to which European prescribers identify with these profiles and the role of these profiles ...
Mariëlle G. Hartjes   +3 more
wiley   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza   +4 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou   +2 more
wiley   +1 more source

The Inaugural NIH‐Wide Strategic Plan for Autoimmune Disease Research (Fiscal Years 2026–2030)

open access: yes
Arthritis &Rheumatology, EarlyView.
Victoria K. Shanmugam   +3 more
wiley   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy